Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients.

Psychopharmacology
F MesottenY G Gelders

Abstract

Risperidone (R 64766) was administered during 4 weeks in increasing doses to 17 psychotic patients, to evaluate the hematological and cardiovascular safety, the therapeutic effect, side effects, effects upon endocrinological parameters and the pharmacokinetic profile. Following a placebo wash-out period of 1 week, the initial dose was 10 mg daily, increasing with 5 mg per week until the maximal dose of 25 mg daily was reached during the 4th week of treatment. Doses up to 20 mg daily resulted in a significant improvement of the total BPRS score and of the different BPRS factor scores; with higher doses, no further clinical benefit was achieved except for the hostility and anxiety-depression factor, while sedation became more prominent. No increase of extrapyramidal symptoms was noticed. Except for the sedation observed with higher doses, risperidone was well tolerated. No clinically relevant effects on cardiovascular and ECG parameters were noticed, and except for a slight increase of aspartate aminotransferase and alanine aminotransferase in one patient, no laboratory abnormalities were observed. Prolactin showed an expected increase, while the other endocrinological parameters revealed no changes. Risperidone had a linear phar...Continue Reading

References

Jan 1, 1985·Psychopharmacology·D L CeulemansP A Janssen
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus

❮ Previous
Next ❯

Citations

Jan 1, 1997·European Archives of Psychiatry and Clinical Neuroscience·H J MöllerH Schubert
Jan 11, 1996·European Journal of Pharmacology·S H Kafka, R Corbett
May 1, 1993·Pharmacology, Biochemistry, and Behavior·R CorbettR W Dunn
Jan 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·K HeinrichH Hruschka
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B GallhoferH Gruppe
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yung-Chieh YenMian-Yoon Chong
Feb 19, 1994·Lancet·M G Livingston
Sep 2, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·P HertelT H Svensson
Jun 10, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Rodríguez-AriasV M Simón
Oct 9, 2002·Clinical and Experimental Pharmacology & Physiology·Miyuki OtaAkira Ota
Apr 7, 2005·Clinical and Experimental Pharmacology & Physiology·Miyuki OtaAkira Ota
Oct 11, 2001·Journal of Clinical Psychopharmacology·Q Cordeiro, H Elkis
Apr 1, 1996·Journal of Clinical Psychopharmacology·M J Byerly, C L DeVane
Aug 1, 1995·Journal of Clinical Psychopharmacology·P CzoborR C Meibach
Jun 1, 1996·Journal of Clinical Psychopharmacology·H D Abraham, A Mamen
Jan 1, 2004·International Journal of Psychiatry in Clinical Practice·Eleonora Tchernichovsky, Pinkhas Sirota
Mar 16, 2001·Expert Opinion on Pharmacotherapy·R C Love, M W Nelson
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
May 30, 2006·Biological Psychiatry·George M AndersonBenedetto Vitiello
Dec 1, 1993·Annals of Emergency Medicine·K BrownE L Hamburg
Mar 6, 2003·Journal of Clinical Pharmacology·Qinying ZhaoJean-Loup Parier
Sep 1, 1995·Acta Neuropsychiatrica·J A den Boer
Mar 14, 2007·International Review of Neurobiology·Anissa Abi-Dargham
Dec 16, 2003·Hospital Medicine·James Paul Pandarakalam

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.